Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the...
August 28, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung...